Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

被引:2
|
作者
Zhang, Nianping [1 ,2 ]
Guo, Peng [3 ]
Zhao, Yan [4 ]
Qiu, Xiao [2 ]
Shao, Shuai [5 ]
Liu, Zhenzhong [6 ]
Gao, Zong [7 ]
机构
[1] Shandong Univ Tradit Chinese Med, Postdoctoral Mobile Stn, Jinan 250355, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China
[3] Jinan Third Peoples Hosp, Dept Neurol, Jinan 250132, Shandong, Peoples R China
[4] Jinan Third Peoples Hosp, Dept Hand & Upper Limb Surg, Jinan 250132, Shandong, Peoples R China
[5] Jingmen Peoples Hosp, Dept Reprod Med, Jingmen 448000, Hubei, Peoples R China
[6] North Sichuan Med Coll, Sch Publ Hlth, Nanchong 637100, Peoples R China
[7] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Neurosurg, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China
关键词
Parkinson 's disease; Puerarin; Pharmacological mechanism; Dopaminergic neurons; Traditional Chinese medicine monomer; PROTECTS DOPAMINERGIC-NEURONS; UBIQUITIN-PROTEASOME SYSTEM; IN-VITRO; ISOFLAVONE PUERARIN; COUPLED RECEPTOR; OXIDATIVE STRESS; PI3K/AKT PATHWAY; O-GLCNACYLATION; MOUSE MODELS; PC12; CELLS;
D O I
10.1016/j.biopha.2024.117101
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Puerarin, a monomer of traditional Chinese medicine, is a key component of Pueraria radix . Both clinical and experimental researches demonstrated that puerarin has therapeutic effects on Parkinson 's disease (PD). Puerarin 's pharmacological mechanisms include: 1) Anti-apoptosis. Puerarin inhibits cell apoptosis through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways. Puerarin also exerts a hormone-like effect against cell apoptosis; 2) Anti-oxidative stress injury. Puerarin inhibits the Nrf2 nuclear exclusion through the GSK-3 beta/Fyn pathway to promote the Nrf2 accumulation in the nucleus, and then promotes the antioxidant synthesis through the Nrf2/ARE signaling pathway to protect against oxidative stress; 3) Neuroprotective effects by intervening in the ubiquitinproteasome system (UPS) and autophagy-lysosomal pathway (ALP). Puerarin significantly enhances the activity of chaperone-mediated autophagy (CMA), which downregulates the expression of alpha-synuclein, reduces its accumulation, and thus improves the function of damaged neurons. Additionally, puerarin increases proteasome activity and decreases ubiquitin-binding proteins, thereby preventing toxic accumulation of intracellular proteins; 4) Alleviating inflammatory response. Puerarin inhibits the conversion of microglia to the M1 phenotype while inducing the transition of microglia to the M2 phenotype. Furthermore, puerarin promotes the secretion of anti-inflammatory factor and inhibits the expression of pro-inflammatory factors; 5) Increasing the levels of dopamine and its metabolites. Puerarin could increase the levels of dopamine, homovanillic acid (HVA) and 3,4dihydroxyphenylacetic acid (DOPAC) in the striatum; 6) Promoting neurotrophic factor expression and neuronal repair. Puerarin increases the expression of glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), thereby exerting a neuroprotective effect. Moreover, the regulation of the gut microbiota by puerarin may be a potential mechanism for the treatment of PD. The current review discusses the molecular mechanisms of puerarin, which may provide insight into the active components of traditional Chinese medicine in the treatment of PD.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Pharmacological mechanisms of the treatment of dyskinesias in Parkinson's disease
    Jiménez-Jiménez, FJ
    Molina, JA
    Ortí-Pareja, M
    REVISTA DE NEUROLOGIA, 1999, 28 (09) : 889 - 898
  • [2] Pharmacological treatment of Parkinson's disease
    Münchau, A
    Bhatia, KP
    POSTGRADUATE MEDICAL JOURNAL, 2000, 76 (900) : 602 - 610
  • [3] Pharmacological treatment of Parkinson’s disease
    G Arabia
    BMC Geriatrics, 10 (Suppl 1)
  • [4] The effects of pharmacological treatment on speech in Parkinson's disease
    Saniens, P.
    De Letter, M.
    Van Maele, G.
    De Bodt, M.
    Van Borsel, J.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S184 - S184
  • [5] Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease
    Kalinderi, K.
    Fidani, L.
    Katsarou, Z.
    Bostantjopoulou, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (12) : 1289 - 1294
  • [6] Novel pharmacological targets for the treatment of Parkinson's disease
    Schapira, Anthony H. V.
    Bezard, Erwan
    Brotchie, Jonathan
    Calon, Frederic
    Collingridge, Graham L.
    Ferger, Borris
    Hengerer, Bastian
    Hirsch, Etienne
    Jenner, Peter
    Le Novere, Nicolas
    Obeso, Jose A.
    Schwarzschild, Michael A.
    Spampinato, Umberto
    Davidai, Giora
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) : 845 - 854
  • [7] Emerging therapies in the pharmacological treatment of Parkinson's disease
    Korczyn, AD
    Nussbaum, M
    DRUGS, 2002, 62 (05) : 775 - 786
  • [8] Novel pharmacological targets for the treatment of Parkinson's disease
    Anthony H. V. Schapira
    Erwan Bezard
    Jonathan Brotchie
    Frédéric Calon
    Graham L. Collingridge
    Borris Ferger
    Bastian Hengerer
    Etienne Hirsch
    Peter Jenner
    Nicolas Le Novère
    José A. Obeso
    Michael A. Schwarzschild
    Umberto Spampinato
    Giora Davidai
    Nature Reviews Drug Discovery, 2006, 5 : 845 - 854
  • [9] Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease
    Amos D. Korczyn
    Miri Nussbaum
    Drugs, 2002, 62 : 775 - 786
  • [10] Pharmacological treatment in Parkinson's disease: Effects on gait
    Smulders, Katrijn
    Dale, Marian L.
    Carlson-Kuhta, Patricia
    Nutt, John G.
    Horak, Fay B.
    PARKINSONISM & RELATED DISORDERS, 2016, 31 : 3 - 13